Searchable abstracts of presentations at key conferences in endocrinology

ea0063p272 | Pituitary and Neuroendocrinology 1 | ECE2019

A retrospective study of 275 cases of pituitary intervention in south great plain region of Hungary

Kupai Krisztina , Fulop Bela , Tiszlavicz Laszlo , Valkusz Zsuzsanna

Objective: Tumors of the pituitary gland and sellar region, called pitiutary adenoma (PA) represent approximatly 10% of all central nervous system tumors. The characteristics of these tumors may vary from population to population.Aim: The aim of this retrospective study was to investigate and understand the clinicopathological characteristics, the invasiveness, tumor features and clinical symptoms of PA in adult patients at south great plain region of Hu...

ea0049ep1388 | Thyroid (non-cancer) | ECE2017

Neuroendocrine progression of medullary thyroid cancer – case report

Sepp Krisztian , Besenyi Zsuzsanna , Tiszlavicz Laszlo , Valkusz Zsuzsanna

: Thyroid cancers represent approximately 1% of new cancer diagnoses. Thyroid malignancies are divided into papillary carcinomas (80%), follicular carcinomas (10%), medullary carcinomas (5–10%), anaplastic carcinomas (1–2%) other rare tumours (primary thyroid lymphomas, primary thyroid sarcomas). The main therapeutic options are surgery (mainly total thyreoidectomy), radioiodine treatment (depending on the type and stage of the tumour), levothyroxine therapy (thyroid...

ea0041ep1109 | Thyroid cancer | ECE2016

Screening and follow up of an extended Hungarian family with familial medullary thyroid cancer

Valkusz Zsuzsanna , Sepp Krisztian , Gardi Janos , Patocs Attila

Medullary thyroid carcinoma (MTC) originates from the parafollicular or C cells of the thyroid gland and represents approximately 10% of all thyroid malignancies. The operational classification of FMTC is four or more family members with MTC without objective evidence of pheochromocytoma (PC) and parathyroid hyperplasia. In multiple endocrine neoplasia type 2A (MEN 2A) and familial medullary thyroid cancer (FMTC), the majority of germline mutations are restricted to specific p...

ea0035oc6.4 | Bone, calcium & vitamin D | ECE2014

The REPEAT Study: An open-label clinical trial evaluating the safety and efficacy of recombinant human parathyroid hormone, rhPTH(1–84), for the treatment of hypoparathyroidism in hungary

Lakatos Peter , Bajnok Laszlo , Lagast Hjalmar , Valkusz Zsuzsanna

In hypoparathyroidism, inadequate levels of parathyroid hormone (PTH) result in hypocalcemia and often hyperphosphatemia. Large doses of calcium (Ca) and active vitamin D are typically used to manage symptoms, although these are often associated with complications and do not address the underlying PTH deficiency. In the phase III REPLACE trial, 24 weeks of treatment with rhPTH(1–84) was associated with maintained serum Ca without urine Ca excretion increases despite clini...

ea0035p567 | Endocrine tumours and neoplasia | ECE2014

Neuroendocrine carcinomas of the thymus: two case reports

Sepp Krisztian , Csajbok Eva , Magony Sandor , Julesz Janos , Valkusz Zsuzsanna

The neuroendocrine tumor of thymus (TNET) is an extremely rare disease. It can occur sporadically or as a part of the multiple endocrine neoplasia (MEN1) syndrome. TNET may secret hormons (ectopic ACTH production). It is a potentially malignant tumor which often develops distant metastases. Its prognostic factors are the tumor size, histological grade, Ki67 index, paraneoplastic symptoms, surgical resection and Masaoka staging. The options for treatment are radical surgery, ch...

ea0022p216 | Clinical case reports and clinical practice | ECE2010

10 years experience with somatostatin analogue (SSA) treatment in multiple endocrin neoplasia type 1 (a case report)

Krisztian Sepp , Zsuzsanna Valkusz , Ildiko Kiss , Laszlo Pavics , Janos Julesz

Multiple endocrine neoplasia (MEN-1) is a rare congenital disease with genetic background. The MEN-1 gene encodes the menin protein, which acts as a tumour suppressor. Mutation of one allele and the inactivation of the other allele of this gene lead to clonal proliferation and to the development of tumours. The clinical manifestation of MEN-1 is a combination of endocrine (most commonly parathyreoid adenomas, entero-pancreatic endocrine tumours, pituitary tumours) and non-endo...

ea0022p250 | Clinical case reports and clinical practice | ECE2010

Different manifestations of polyglandular autoimmune syndrome in HLA-identical monozygous twins

Csajbok Eva , Magony Sandor , Valkusz Zsuzsanna , Panczel Pal , Julesz Janos

The polyglandular autoimmune syndromes (PAS) comprise a wide spectrum of autoimmune disorders and are divided into a very rare juvenile (type I) and a relatively common adult type with (type II) or without adrenal failure (PAS III). For PAS II/III, susceptibility genes are known inreasing the risk for developing autoimmune disorders, but without being causative. Actual diagnosis of PAS involves serological measurement of organ-specific autoantibodies and subsequent functional ...

ea0049ep742 | Endocrine Disruptors | ECE2017

The effects of halogenated-hydrocarbon uron herbicides, as endocrine disruptor compounds on the oxytocin (OT) hormone regulation in vitro

Sepp Krisztian , Valkusz Zsuzsanna , Molnar Zsolt , Laszlo Anna , Alapi Tunde , Radacs Marianna , Galfi Marta

The biological organisms are complex systems regulated by the homeostatic back-end network. In these days the growing environmental loads (from industry, household, etc.) contain chemical exposure eg. halogenated hydrocarbons (monuron: MU (C9H11ClN2O), diuron: DU (C9H10Cl2N2O)), which can be endocrine disruptor compounds (EDCs). Synthesis, release of hormones and cell processes of endocrine cells, and...

ea0041ep587 | Endocrine Disruptors | ECE2016

The effects of endocrine disruptors on the in vitroAVP hormone regulation

Sepp Krisztian , Valkusz Zsuzsanna , Molnar Zsolt , Budai I , Alapi Tunde , Radacs Marianna , Galfi Marta

Introduction: Endocrine disruptor compounds (EDCs) are chemicals that may interfere with the endocrine system and produce adverse developmental, reproductive, neurological and immune effects.These agents can be found in household, in the industry and in our environment.Endocrine disruptors are substances that interfere with the synthesis, secretion, transport, binding, action, or elimination of natural hormones in the body that are responsible for development, behavio...

ea0037ep151 | Reproduction, endocrine disruptors and signalling | ECE2015

The effects of endocrine disruptors on the in vitro hormone regulation of rat pituitary

Valkusz Zsuzsanna , Radacs Marianna , Palfoldi Regina , Molnar Zoltan , Sepp Krisztian , Laszlo Anna , Alapi Tamas , Galfi Marta

Endocrine disruptor compounds (EDCs) may cause disorders and alter the normal hormone synthesis and/or release.Aim was to investigate the effects of EDCs on normal hypophysis regulation; particularly the arginine–vasopressine (AVP) activated ACTH release from adenohypophysis cells and the monoamine activated AVP release from neurohypophysis cells.Primary monolayer cell cultures prepared from Wistar rat hypophyses. Separated ad...